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The	glycogen	synthase	kinase-3	(GSK-3)	family	of	serine/threonine	kinases	consists	of	2	highly	related	
isoforms,	α	and	β.	Although	GSK-3β	has	an	important	role	in	cardiac	development,	much	remains	unknown	
about	the	function	of	either	GSK-3	isoform	in	the	postnatal	heart.	Herein,	we	present	what	we	believe	to	be	the	
first	studies	defining	the	role	of	GSK-3α	in	the	mouse	heart	using	gene	targeting.	Gsk3a–/–	mice	over	2	months	
of	age	developed	progressive	cardiomyocyte	and	cardiac	hypertrophy	and	contractile	dysfunction.	Following	
thoracic	aortic	constriction	in	young	mice,	we	observed	enhanced	hypertrophy	that	rapidly	transitioned	to	
ventricular	dilatation	and	contractile	dysfunction.	Surprisingly,	markedly	impaired	β-adrenergic	responsive-
ness	was	found	at	both	the	organ	and	cellular	level.	This	phenotype	was	reproduced	by	acute	treatment	of	WT	
cardiomyocytes	with	a	small	molecule	GSK-3	inhibitor,	confirming	that	the	response	was	not	due	to	a	chronic	
adaptation	to	LV	dysfunction.	Thus,	GSK-3α	appears	to	be	the	central	regulator	of	a	striking	range	of	essen-
tial	processes,	including	acute	and	direct	positive	regulation	of	β-adrenergic	responsiveness.	In	the	absence	of	
GSK-3α,	the	heart	cannot	respond	effectively	to	hemodynamic	stress	and	rapidly	fails.	Our	findings	identify	
what	we	believe	to	be	a	new	paradigm	of	regulation	of	β-adrenergic	signaling	and	raise	concerns	given	the	rapid	
expansion	of	drug	development	targeting	GSK-3.
Introduction
The glycogen synthase kinase-3 (GSK-3) family consists of 2 
isoforms, α and β, which are 98% identical within their kinase 
domains but differ substantially in their N- and C-terminal 
sequences (1). Unlike most protein kinases, GSK-3 is typical-
ly active in unstimulated cells and is inhibited in response to a 
variety of inputs (1). Since GSK-3–mediated phosphorylation of 
substrates usually leads to inhibition of those substrates, the end 
result of stimulus-induced inhibition of GSK-3 is typically acti-
vation of its downstream targets. Innumerable factors have been 
reported to be bona fide substrates of GSK-3 (2, 3).
Most of the attention on this family has centered on GSK-3β, 
which, since its discovery, has been reported to regulate an astonish-
ing variety of cellular processes. However, this bias toward GSK-3β as 
the dominant isoform may go back many years to studies in which 
mammalian GSK-3β was better able than GSK-3α to rescue the friz-
zled phenotype in Drosophila, which resulted from a mutation in fly 
GSK-3 (Zw3/shaggy) (4, 5). In fact, recent studies done in ES cells in 
which Gsk3a, Gsk3b, or both have been deleted demonstrate that the 2 
isoforms are entirely redundant in terms of regulating the canonical 
Wnt pathway (6). Thus, not until 3 out of 4 alleles of Gsk3a and Gsk3b 
are deleted is there any spontaneous activation of Wnt/β-catenin sig-
naling, and not until all 4 are deleted is the activation marked.
However, GSK-3s are clearly not redundant in all functions. For 
example, GSK-3α is not able to compensate for loss of GSK-3β 
during cardiac development (7). Indeed, the hearts of embryos in 
which Gsk3b has been deleted were characterized by a hypertrophic 
myopathy that was due primarily to hyperproliferation of cardio-
myocytes (7). This led to near obliteration of the RV and LV cavities 
and, together with structural defects, including double outlet RV 
and ventricular septal defect, common congenital abnormalities in 
humans, uniformly led to late embryonic or immediate postnatal 
death. Furthermore, based on studies in ES cells in which one or 
the other isoform has been deleted, GSK-3β appears to promote 
cardiomyocyte differentiation, whereas GSK-3α plays a much 
more minor role (3, 7).
Although the above findings clearly demonstrate that 
GSK-3β plays a dominant role in cardiac development, the role of 
the isoforms in the postnatal heart is not known. This is due to the 
fact that all studies to date have used transgenesis, knockin of acti-
vated mutants, or nonselective small molecule inhibitors (e.g., BIO) 
(8–14). None of these strategies allow one to define the true biology 
of GSK-3s or an understanding of isoform-specific effects.
Not surprisingly, some of these studies have reached seemingly 
contradictory conclusions, particularly concerning the role of 
GSK-3α. For example, work from the same laboratory alternate-
ly reported that constitutively active GSK-3α suppressed pres-
sure overload–induced hypertrophy in a transgenic model but 
enhanced hypertrophy in a knockin model (13, 14). Further com-
plicating understanding, the strategy used in these models (muta-
tion of the inhibitory serine 21 phosphorylation site of GSK-3α 
and serine 9 phosphorylation site of GSK-3β to alanine residues) 
blocks only 1 mechanism by which GSK-3α can be inhibited (i.e., 
PI3-kinase–mediated activation of Akt) and does not affect Wnt-
mediated or p38-MAPK–mediated inhibition (15–17). Finally, to 
Conflict	of	interest: The authors have declared that no conflict of interest exists.
Citation	for	this	article:	J Clin Invest. 2010;120(7):2280–2291. doi:10.1172/JCI41407.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 120   Number 7   July 2010 2281
date, no studies have examined possible metabolic effects of GSK-
3s and how they might affect cardiac function, even though this 
is a critical factor in GSK-3–regulated disease processes, including 
glucose intolerance and diabetes (18, 19).
Herein, we used a mouse in which Gsk3a has been deleted (KO) 
to define its roles in the heart. We found critical roles for this 
kinase in cardiac growth, pathologic hypertrophy, maintenance 
of mitochondrial integrity, and regulation of contractile func-
tion. Most importantly, we found that the response to β-adrener-
gic stimulation, which is one of the most critical responses in the 
heart to stress, if not the most important one, depends on GSK-3α. 
In the absence of GSK-3α, there is a gradual deterioration in 
LV function that is dramatically accelerated when the heart is 
exposed to hemodynamic stress.
Results
Hypertrophy in the GSK-3α KO. The creation of the GSK-3α KO 
mouse was previously described (6, 20). Briefly, a pCAGGS 
(chicken β-actin) Cre deleter mouse strain generated by Nagy 
(21), which expresses Cre in all tissues, was crossed with the Gsk3a 
floxed mouse (exon 2) to generate the KO mice. Subsequently, 
the Cre transgene was bred out, and Cre was no longer detect-
able by RT-PCR in the mice used herein. Importantly, there was 
no compensatory upregulation of GSK-3β in the heart following 
deletion of Gsk3a (Figure 1A). As previously reported, Gsk3a KO 
mice appeared normal at birth (7). However, beginning after 3 
months of age, cardiac hypertrophy developed (Tables 1 and 2). 
Cardiac hypertrophy was due, at least in part, to cardiomyocyte 
hypertrophy, since cardiomyocyte size was significantly increased 
in the KO mice (Figure 1B).
The hypertrophy was not due to hypertension, since LV systolic 
pressures (LVSPs) were not increased in the KO mice at up to 6 
months of age (see below). The hypertrophy was also not likely due 
to volume overload, since LV end-diastolic dimension (EDD), as 
assessed by echocardiography, was not increased in the KO mice at 
up to 6 months of age (Table 2) and LV end-diastolic pressure was not 
increased in the KO mice until 6 months of age (data not shown).
Given the key role of GSK-3 in regulating glycogen storage, we 
asked whether enhanced glycogen storage, which leads to cardiac 
hypertrophy in patients with mutations in the γ2 subunit of AMPK 
(22), could account for the hypertrophy in the Gsk3a–/– mice. 
Although we did find that GSK-3α regulated phosphorylation sta-
tus of the critical Ser641 residue of glycogen synthase (Figure 1C) 
and, consequently, glycogen storage in the heart, the absolute 
amount of glycogen in the heart was small (0.05% of that in the 
liver), and the increase compared with WT littermates was mini-
mal (12.5 ± 0.36 vs. 15.7 ± 0.95 mg/g of tissue; P = 0.06). Thus, 
increased glycogen storage did not account for the hypertrophy.
We then turned to signaling pathways downstream of GSK-3 
that regulate hypertrophic growth. One of these is mTOR com-
plex 1 (mTORC1), the master regulator of protein translation 
Figure 1
Deletion of Gsk3a leads to cardiac hypertrophy. (A) Deletion of Gsk3a does not lead to compensatory upregulation of GSK-3β. Immunoblot of 
heart lysates from 6-month-old Gsk3a+/+ (WT) and Gsk3a–/– (KO) mice, blotted with anti–GSK-3α (top), anti–GSK-3β (middle), or loading control 
(anti-GAPDH, bottom). (B) Cardiomyocyte size determination. Cardiomyocytes were isolated from 6-month-old KO and WT mice, as described 
in Methods. Cell area was then determined in 551 KO myocytes from mice (n = 6) and 576 WT myocytes from mice (n = 6), as described in 
Methods. #P < 0.01 versus WT. (C) GSK-3α regulates phosphorylation of glycogen synthase, Ser641. Mice were fasted overnight, and then 
heart lysates were immunoblotted with anti–phospho–glycogen synthase (GS-pSer641), anti–glycogen synthase (GS), or GAPDH. The image is 
representative of findings from WT (n = 6) and KO (n = 6) mice. (D) Dysregulation of mTORC1 in the KO mice. Lysates of hearts from 4-month-old 
WT and KO mice were immunoblotted for (top to bottom) phospho–4E-BP1 Thr37/46, phospho–4E-BP1 Ser65, total 4E-BP1, phospho-p70S6K 
Thr389, total p70S6K, or GAPDH. Note the increase in phosphorylation of 4E-BP1 at both sites and of p70S6K in the KO.
Table 1
Gravimetric data for the Gsk3a knockout mouse heart
	 n	 BW	(g)	 HW	(mg)	 HW/BW	ratio
2	months	old
WT 23 26.8 ± 3.36 102.4 ± 10.96 3.88 ± 0.128
KO 25 27.5 ± 3.13 107.9 ± 13.33 3.97 ± 0.144
4	months	old
WT 11 32.7 ± 1.96 137.9 ± 11.94 3.96 ± 0.290
KO 14 35.8 ± 2.56 169.9 ± 8.25A 4.84 ± 0.249A
6	months	old
WT 10 35.6 ± 2.04 146.3 ± 14.92 4.10 ± 0.273
KO 21 37.8 ± 2.22 184.7 ± 16.19A 4.89 ± 0.129A
Values are mean ± SD. AP < 0.05, KO versus WT mice.
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that is inhibited following GSK-3–mediated phosphorylation 
of Tsc2 (23). We found significant activation of mTORC1 based 
on enhanced phosphorylation of 2 of its substrates, 4E-BP1 and 
p70S6 kinase (Figure 1D). Thus GSK-3α is a key negative input 
into mTORC1 signaling, and loss of GSK-3α leads to inappropri-
ate activation of mTOR in the heart. In contrast, we saw no acti-
vation of other hypertrophic signaling pathways including Akt 
(data not shown) and p38 MAPK, but did find modest activation 
of ERK1/2 in the basal state (see below).
Pressure overload hypertrophy in the GSK-3α KO mice. We then 
examined the effect of deletion of Gsk3a on the response to pres-
sure overload induced by transverse aortic constriction (TAC) at 
4 months of age. Mice that underwent TAC had an increase in 
hypertrophy that was more pronounced in KO compared with 
WT mice (Figure 2A). This was associated with increased expres-
sion of atrial natriuretic peptide (3.7-fold in KO mice undergoing 
TAC [KO/TAC] vs. WT mice undergoing TAC [WT/TAC]; P = 0.01) 
and a trend toward increased brain natriuretic peptide (1.5-fold in 
KO/TAC vs. WT/TAC; P = 0.06).
When we plotted heart weight/body weight (HW/BW) versus 
LVSP, the KO mice had much higher HW/BW at significantly 
lower systolic pressures (Figure 2, B and C). This was associ-
ated with reduced fractional shortening (Figure 2D) and more 
markedly reduced maximal first derivative of LV pressure rise 
(+dP/dt) and fall (–dP/dt) (Figure 2, E and F). Since the degree of 
TAC was the same in WT and KO mice, the data, taken together, 
are consistent with an enhanced hypertrophic response and an 
inability of the heart of the GSK-3α KO mouse to generate a 
pressor response to TAC.
Although substantially greater in the KO mice, the full magni-
tude of the difference in the hypertrophic response between WT 
and KO mice was somewhat difficult to compare in the 4-month-
old mice, given the baseline differences in heart weight (Tables 1 
and 2 and Figure 2A). Therefore, we used TAC in 2-month-old 
mice, a time at which there are no differences between WT and KO 
mice in baseline LV mass (Table 1 and Figure 3A). We then followed 
the mice with weekly echocardiography for 3 weeks. Within 1 week, 
calculated LV mass in KO and WT mice started to diverge, and 
at 2 and 3 weeks after TAC, the differences were statistically sig-
nificant (Figure 3, A and E). In contrast to the WT mice, fractional 
shortening progressively fell over the 3-week period in the KO mice 
(Figure 3F). Furthermore, in con-
trast to WT mice, EDD increased 
significantly in the KO mice at the 
3-week time point, consistent with 
adverse remodeling occurring early 
after TAC (Figure 3C). This adverse 
remodeling was again associated 
with an inability of the KO mice 
to generate a pressor response to 
TAC (Figure 3D). The KO hearts 
were also notable for significant 
replacement fibrosis, consistent 
with cell loss. This was widespread 
and involved approximately 14% 
of the surface area of the LV of the 
KO hearts (Figure 3F).
Contractile dysfunction in the KO 
heart. Not only was there marked 
LV dysfunction after TAC in the 
KO heart, modest LV dysfunction was also apparent in the non-
stressed KO heart, as assessed by echocardiography at both 4 
and 6 months of age (Table 2). To get a sense of the factors that 
might contribute to the LV dysfunction, we examined transmis-
sion EMs from the hearts of 6-month-old KO mice. We found 
striking abnormalities of mitochondrial structure, characterized 
by markedly swollen mitochondria, containing only remnants 
of cristae (Figure 4, A and B). These findings were relatively 
widespread and strongly suggested opening of the mitochon-
drial permeability transition pore. Of note, these findings were 
not present in the 2-month-old or 4-month-old hearts (data not 
shown). Thus, the mitochondrial abnormalities likely exacerbat-
ed the LV dysfunction seen in the 6-month-old mice, but other 
processes were also involved, since the mitochondrial abnormal-
ities were not present at the earlier time points.
We were most struck by the inability of the KO heart to mount 
a contractile response in the setting of pressure stress, and we 
explored potential mechanisms. Since the β-adrenergic system 
is critical for the heart’s response to stress, we examined adren-
ergic responsiveness in the hearts of the 6-month-old KO mice 
exposed to graded isoproterenol infusion. These studies were 
done in mice in the basal state (i.e., in the absence of prior TAC). 
We found a significant reduction in the response of the KO heart 
to isoproterenol compared with that of the WT heart (Figure 4, 
C–F). The LVSP response was reduced, albeit not significantly 
(Figure 4C), but there was a markedly blunted +dP/dt (Figure 
4D) and –dP/dt (Figure 4E) response in the KO compared with 
the WT heart. The heart rate response to isoproterenol was also 
blunted (Figure 4F).
At 2 months of age, despite echocardiographic fractional short-
ening being normal (Figure 3B and Tables 1 and 2), the contractile 
responses to β-adrenergic stimulation (LVSP and +dP/dt) were sig-
nificantly depressed (Figure 5, A and B). –dP/dt was also reduced 
(Figure 5C). The depression of β-adrenergic responsiveness was 
also evident at the single cell level, though it did not reach statis-
tical significance in the myocytes isolated from 2-month-old KO 
mice (Figure 6, A and B).
We then explored mechanisms of the impaired response to 
β-adrenergic stimulation. We first wanted to rule out the possi-
bility that the alterations in β-adrenergic responsiveness were a 
consequence, as opposed to the cause, of the LV dysfunction. That 
Table 2
Echocardiographic data for the Gsk3a knockout mouse heart
	 n	 LV	mass	(mg)	 LVPW;d	(mm)	 EDD	(mm)	 ESD	(mm)	 FS	(%)
2	months	old
WT 18 109.9 ± 11.15 0.80 ± 0.065 4.00 ± 0.245 2.71 ± 0.210 30.12 ± 3.066
KO 17 111.7 ± 17.05 0.82 ± 0.075 4.04 ± 0.341 2.71 ± 0.395 29.97 ± 4.640
4	months	old
WT 18 130.2 ± 15.74 0.83 ± 0.092 4.18 ± 0.230 2.66 ± 0.286 30.89 ± 3.399
KO 17 150.7 ± 26.18B 0.94 ± 0.062B 4.20 ± 0.294 2.67 ± 0.398 28.47 ± 3.291A
6	months	old
WT 23 139.0 ± 21.00 0.88 ± 0.087 4.23 ± 0.317 2.72 ± 0.352 35.93 ± 5.011
KO 23 172.1 ± 29.11B 1.00 ± 0.096A 4.30 ± 0.315 2.98 ± 0.322A 30.22 ± 3.534B
LV mass (in mg) was calculated on M-mode and 2-dimensional echocardiography. Values are mean ± SD. 
LVPW;d, diastolic LV posterior wall; ESD, end-systolic dimension; FS, fractional shortening. AP < 0.05,  
BP < 0.01 KO versus WT mice.
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is, we wanted to exclude an intrinsic abnormality of the myocyte 
leading to the decreased responsiveness. Therefore, we treated 
4-month-old WT and KO mice with NKH477, a water soluble for-
skolin derivative that increases cAMP levels in the heart by directly 
activating adenylyl cyclase (24). Graded infusion of NKH477 mark-
edly increased cAMP levels in the heart, and the increase was com-
parable in WT versus KO mice (Figure 7A). Furthermore, cardiac 
responsiveness to increases in cAMP was equivalent in WT versus 
KO mice (Figure 7, B–E), ruling out an intrinsic contractile defect 
as the cause of the reduced responsiveness in the KO.
We then asked whether the defect in β-adrenergic respon-
siveness was due to an impairment in cAMP generation. We 
Figure 2
Exaggerated hypertrophy and impaired cardiac function in the 4-month-old KO mouse subjected to pressure stress. Four-month-old WT and KO 
mice were subjected to TAC or sham TAC for 3 weeks, as described in Methods. (A) At sacrifice, HW/BW ratios (a measure of cardiac hyper-
trophy) were determined. (B) HW/BW is plotted as the dependent variable, with LVSP as the independent variable. Note the marked increase 
in HW/BW at all LVSPs for the KO mice (black triangles) when compared with WT mice (red circles). Also note that the KO mice were unable to 
generate LVSPs of more than 110 mmHg. LVSP (C), fractional shortening (FS) (D), +dP/dt (E), and –dP/dt (F) are shown graphically. Note that 
all functional parameters are depressed in the KO mice. n = 7 WT and 9 KO sham mice; n = 10 WT/TAC and 13 KO/TAC (A); n = 19 WT/TAC 
and 16 KO/TAC (B); n = 6 WT and 7 KO sham mice; n = 10 WT/TAC and 5 KO/TAC (C–F).
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examined cAMP production in response to isoproterenol infu-
sion in the KO mouse and found that it was markedly reduced 
compared with that of the WT mouse, both in the heart in vivo 
(Figure 8A) and in cardiomyocytes isolated from the KO mouse 
(Figure 8B). To confirm that the dysregulation of cAMP produc-
tion in the KO mouse was due to a direct effect of deletion of 
Gsk3a, we used SB415286, a relatively selective, small molecule 
inhibitor of GSK-3 (25, 26). Pretreatment of WT cardiomyocytes 
for 30 minutes with SB415286 led to a significant reduction in 
the contractile response to isoproterenol, mimicking the find-
ings in the KO cells (Figure 8C). Furthermore, SB415286 sig-
nificantly blunted isoproterenol-induced cAMP production in 
neonatal rat ventricular myocytes (NRVMs), although the cells 
were comparable in their ability to generate cAMP following for-
skolin (Figure 8D).
We then explored the consequences of the impaired cAMP pro-
duction on downstream signaling. We first examined a central 
target of PKA, phospholamban (PLN), in 2-month-old mice. 
Isoproterenol-induced phosphorylation of PLN at the PKA (and 
CamKII) sites was markedly reduced in the KO mice (Figure 8E). 
These alterations in β-adrenergic–mediated PLN phosphoryla-
tion can be expected to lead to inhibition of SERCA2 and, if 
sustained, to impaired calcium handling and, eventually, con-
tractile dysfunction.
Based on our studies, we knew that the defect in cAMP produc-
tion was upstream of adenylyl cyclase and therefore was likely 
very proximal in the signaling cascade. A parallel signaling path-
way to the adenylyl cyclase/cAMP/PKA pathway that is typically 
activated when the adenylyl cyclase/cAMP response is downregu-
lated by β-arrestin involves β-arrestin–mediated internalization 
of receptor and activation of ERK1/2 (27, 28). Although ERK1/2 
was only minimally activated in the basal state in the KO hearts, 
isoproterenol-induced ERK1/2 activation was significantly 
increased in the KO mice (Figure 8F).
Our studies, taken together, demonstrate that β-adrenergic 
responsiveness is directly regulated by GSK-3α, and GSK-3α–medi-
ated positive regulation of β-adrenergic responsiveness is essential 
to the heart’s adaptation to stress. In the absence of GSK-3α, the 
stressed LV rapidly remodels and fails.
Discussion
In this manuscript, we identify GSK-3α as a critical regulator of 
hypertrophic growth of the nonstressed heart, of the hypertro-
phic response to pressure load, and of maintenance of contractile 
function, particularly in the setting of stress. In the absence of 
GSK-3α, a spontaneous cardiomyopathy develops that is charac-
terized by relatively marked hypertrophy and modest LV dysfunc-
tion, with striking mitochondrial structural abnormalities later 
in life. Most importantly, we find that GSK-3α is a critical and 
direct regulator of β-adrenergic responsiveness. In the absence of 
GSK-3α, the LV is unable to adapt to pressure stress, leading to a 
rapid deterioration in function and to decompensation, including 
a striking inability to sustain a pressor response. This culminates 
in adverse remodeling with LV dilatation. How does deletion of 
Gsk3a lead to these phenotypes?
GSK-3α regulates hypertrophy. The role of GSK-3β in cardiac hyper-
trophy has been examined extensively by several groups, and the 
vast majority of studies have found that expression of either WT or 
a constitutively active S9A mutant repressed hypertrophy (8–14). 
However, based on studies with overexpression of a dominant 
inhibitory mutant of GSK-3β, which showed no enhancement 
of hypertrophy following TAC, it was not clear what role, if any, 
inhibition of GSK-3β played in the response (12). Findings with 
GSK-3α have been even less clear. Whereas a constitutively active 
transgenic repressed the hypertrophic response to TAC, the same 
mutant expressed in a knockin model showed an increased hyper-
trophic response (13, 14). These disparate and confusing findings, 
which led Sugden et al. to state “we just do not know whether to 
inhibit or activate GSK-3, or simply not to interfere” (29), highlight 
the need to examine loss-of-function approaches that do not rely 
on transgenesis. Our data clearly identify a key role for GSK-3α 
as a negative regulator of hypertrophic growth, whether it be in 
response to stress or not.
In screening for mechanisms by which GSK-3α regulates hyper-
trophy, we identified mTORC1 as a key target of the kinase, and 
loss of GSK-3α cannot be compensated for by GSK-3β, in regards 
to this pathway. This is surprising, since the few studies done to 
date have focused on GSK-3β and its role in regulating mTORC1 
downstream of Wnt signaling (30, 31). Our studies identify GSK-3α 
as a central regulator of mTORC1 in hypertrophic signaling. In the 
absence of GSK-3α, activity of mTORC1 is significantly increased. 
Given the critical role played by mTORC1 in regulating the protein 
translation machinery (30), this is very likely to be a key mechanism 
by which GSK-3α regulates the hypertrophic response. In addition 
to dysregulation of mTORC1, it is likely that the contractile dys-
function seen, especially later in the life of the KO mouse, plays a 
role in the increased hypertrophy as a maladaptive response.
GSK-3α regulates contractile function. Prior studies examining 
effects of GSK-3s on TAC-induced LV dysfunction have sug-
gested that increased activity of GSK-3α, by either transgenesis 
or knockin, led to declines in LV function, suggesting GSK-3α 
signaling is detrimental (13, 14). In distinct contrast, our loss-
of-function studies identify a clear and critical role for GSK-3α 
in preserving LV function in the setting of pressure stress. In 
the presence of GSK-3α, hearts developed compensated hyper-
trophy in response to TAC, whereas in the absence of GSK-3α, 
Figure 3
TAC in 2-month-old KO mice. Mice underwent echocardiography 
and then were subjected to TAC or sham TAC. Mice were followed 
with weekly echocardiography, until sacrifice at 3 weeks after TAC. 
(A) LV mass. Note the exaggerated hypertrophic response in the 
KO mice. Black triangles represent WT mice subjected to TAC; red 
circles represent KO mice subjected to TAC; and green and blue 
squares represent WT and KO shams, respectively. (B) Fractional 
shortening in the KO mice progressively declined over the 3 weeks 
after TAC, whereas fractional shortening in the WT mice remained 
stable. (C) EDD progressively declined in WT and KO mice for the 
first 2 weeks but then increased sharply in the KO mice, consistent 
with adverse remodeling/dilatation. (A–C) P values are for the com-
parison between WT versus KO mice subjected to TAC. n = 8 WT 
and 8 KO sham mice; n = 20 WT/TAC and 20 KO/TAC. (D) LVSP, 
measured by invasive hemodynamic evaluation, was decreased in 
the KO mice subjected to TAC. n = 8 WT and 8 KO sham mice; 
n = 11 WT/TAC and 9 KO/TAC. (E) Morphometrics (hypertrophy). 
HW/BW was determined at sacrifice in KO and WT mice undergoing 
TAC or sham surgery. n = 8 WT and 8 KO sham mice; n = 9 WT/TAC 
and 11 KO/TAC. (F) Fibrosis in the KO mice. WT and KO mice that 
underwent TAC were sacrificed at 3 weeks. Sections of heart tissue 
were stained with Masson’s trichrome. The percentage of fibrosis 
was determined from 10 random images taken from each of 4 KO 
and 4 WT mice. Original magnification, ×200.
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the hearts undergo striking and accelerated adverse remodel-
ing, with decompensation. While the marked disruption of 
mitochondrial structural integrity may have played a role in 
the LV dysfunction, given the late appearance of this finding 
(at 6 months), this is clearly not the primary defect. Rather, we 
believe that our studies identify the critical mechanism underly-
ing the protective effects of GSK-3α in the stressed heart to be 
maintenance of β-adrenergic responsiveness. In the absence of 
GSK-3α, there is marked dysregulation of β-adrenergic signal-
ing that results in markedly reduced phosphorylation of PLN. 
The altered β-adrenergic signaling is apparent prior to the mito-
chondrial abnormalities and prior to hypertrophy, suggesting it 
is not a secondary response. This is supported by the findings 
with the forskolin derivative, NKH477 (in response to which the 
KO mouse had a comparable increase in contractile performance 
to that of the WT mouse), and with the small molecule inhibitor 
that acutely recapitulated the altered β-adrenergic responsive-
ness in WT mouse cardiomyocytes and in NRVMs.
Our studies indicate that GSK-3α interacts with the β-adren-
ergic system above the level of PKA, since cAMP production is 
Figure 4
Ultrastructural abnormalities and impaired β-adrenergic responsiveness in the KO mouse. (A and B) Mitochondrial structural abnormalities in 
the KO mouse. Six-month-old WT (A) and KO (B) mouse hearts were fixed and processed for transmission EM. In the KO, images show marked 
swelling of many mitochondria, with only remnants of cristae remaining. For comparison, several normal mitochondria are scattered throughout 
the section and are also evident in A. Original magnification, ×5,000. (C–F) Impaired response to graded isoproterenol (ISO) infusion in 6-month-
old KO versus WT mice. Mice were subjected to graded isoproterenol infusion, as described in Methods. LVSP (C), +dP/dt (D), –dP/dt (E), and 
heart rate (HR) (F) responses are shown. P values, comparing KO to WT mice, are displayed for each of the doses of isoproterenol. n = 8 WT 
and 13 KO mice. bs, basal.
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reduced in the KO mice, and above the level of adenylyl cyclase, 
since forskolin-induced cAMP production was not reduced 
by treatment of WT cardiomyocytes with the GSK-3 inhibitor 
(Figure 8D). Thus the site of interaction is very proximal, presum-
ably at the receptor/G protein–coupled receptor kinase/β-arrestin 
level. The decreased β-adrenergic responsiveness, taken together 
with enhanced ERK1/2 activation in the KO mouse, suggests 
increased β-arrestin activity is involved, since β-arrestin leads to 
both downregulation of β-adrenergic signaling through Gs/ade-
nylyl cyclase/cAMP and increased ERK1/2 signaling via increased 
internalization of receptors and ERKs.
The physiological role of this pathway seems clear: GSK-3α 
normally serves as a positive feedback loop to enhance β-adren-
ergic signaling. Given that PKA can phosphorylate GSK-3α, 
thereby inhibiting the kinase (32, 33), this would provide a 
mechanism for limiting β-adrenergic signaling. Obviously, how-
ever, if the inhibition is marked and sustained, serious adverse 
consequences can result.
Potential clinical implications and conclusions. Our data underline 
the critical role that GSK-3α plays in the heart’s response to 
stress. This is a significant concern, given the proposed use of 
inhibitors of GSK-3 as insulin sensitizers and as agents to treat 
bipolar disorders and a host of other disease states, including 
neurodegenerative disorders and ischemic injury (2, 18, 19, 25, 
34, 35). On the other hand, in patients with preserved LV func-
tion, moderate inhibition of GSK-3α could potentially be used 
as a novel strategy to achieve β-blockade, without leading to 
the well-described β-blocker–induced deteriorations in glucose 
control (36). However, given our findings in the KO mouse, 
the toxic-to-therapeutic ratio of any such inhibitor would be 
a major concern.
In summary, we believe we have identified a novel and central 
role for GSK-3α in regulating contractile function, particularly in 
the setting of stress, and this is mediated via direct regulation of 
the β-adrenergic signaling pathway.
Methods
Antibodies. Antibodies used were directed against GSK-3α (catalog 9338), 
GSK-3β (catalog 9315), glycogen synthase (catalog 3893), glycogen syn-
thase phosphorylated at Ser641 (catalog 3891), elongation factor 4E-
binding protein 1 (4E-BP1) (catalog 9644), 4E-BP1 phosphorylated 
at Thr37/46 (catalog 9459), 4E-BP1 phosphorylated at Ser65 (catalog 
9451), and p70S6K phosphorylated at Thr389 (catalog 9206) (all from 
Cell Signaling Technology). p70S6K (catalog 611260) was from BD Bio-
sciences — Transduction Laboratories. PLN, clone 1 (catalog 05-205) was 
from Millipore. PLN phosphorylated at Ser16 (catalog A010-12) or at 
Thr17 (catalog A010-13) were from Badrilla Ltd. GAPDH (catalog RDI-
TRK5D4-6C5) was from Research Diagnostics.
Figure 5
Impaired response to graded isoproterenol infusion in 2-month-old KO versus WT mice. LVSP (A), +dP/dt (B), and –dP/dt (C) were all reduced 
in the KO mice. P values, comparing KO to WT mice, are displayed for each of the doses of isoproterenol. n = 5 WT and 7 KO mice.
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Chemicals. The GSK-3 inhibitor, SB415286 (catalog S3567), the adeny-
lyl cyclase activator, forskolin (catalog F6886), and the protease and 
phosphatase inhibitor cocktails (catalog P8430, P2850) were from Sigma-
Aldrich. Isoproterenol was from Hospira (catalog 0409-1410-05).
Immunoblotting. LV tissue was homogenized in 10 volumes of lysis 
buffer (50 mM Tris-HCl [pH 7.4]), 150 mM NaCl, 1 mM EDTA, 0.25% 
sodium deoxycholate, 1% NP-40, with the protease inhibitor cocktail 
and phosphatase inhibitor cocktail present. After homogenization, the 
homogenates were centrifuged at 15,000 g for 15 minutes and separated 
into NP-40–soluble supernatant and insoluble pellet. Protein concentra-
tion in the supernatant was quantified with the bicinchoninic acid protein 
assay (catalog 23225; Pierce). Equal amounts of proteins were subjected 
to SDS-PAGE and subsequently were transferred to nitrocellulose mem-
branes. Primary antibody incubations were performed at 1:1,000 dilution. 
All incubations were done at 4°C, overnight. The secondary antibody used 
was Alexa Fluor 680 (Molecular Probes), at 1:3,000 dilution for 1 hour at 
room temperature. Membranes were scanned with the Odyssey Infrared 
Imaging System (LI-COR).
Myocyte isolation and determination of cardiomyocyte surface area. Mouse LV 
myocytes were isolated as previously described (37, 38). The percentage of 
rod-shaped myocytes was greater than 70%. Isolated cardiomyocytes were 
fixed in 0.1 M PBS containing 2% paraformaldehyde and 2.5% glutaralde-
hyde. A 30 μl suspension of isolated myocytes were loaded onto positively 
charged slides and air dried. Myocytes were then placed in 0.1 M glycine 
in PBS for 30 minutes and then were washed with PBS. Cells were per-
meabilized in 1% Triton X-100 in PBS (pH 7.2) at room temperature for 
20 minutes. Cells were then washed in PBS and incubated in 10% Wheat 
Germ Agglutinin (catalog F49; Biomeda) in PBS with 2% BSA for 1 hour. 
Slides were washed 3 times with PBS, for 10 minutes each. Slides were then 
coated with Immo-Mount Mounting Medium for fluorescence (catalog 
H-1000; Vector). The surface area of cardiomyocytes was then quantified 
using NIS-Elements Imaging Software (Nikon) (39).
Contractile function in isolated cardiomyocytes. Ventricular myocytes were iso-
lated as described above. Myocytes were maintained at room temperature 
in 5% CO2 and 95% O2 and were used within 8 hours of isolation. Myocytes 
were placed in a chamber mounted on an inverted Nikon microscope and 
perfused with Tyrode’s solution containing 1 mM Ca2+. Cells were paced 
at 1 Hz and contractions were measured with a video edge detector as 
described previously (37, 38, 40).
cAMP assay. For determination of cAMP content, we used the EIA Kit 
for Cell and Tissue Lysates from BIOMOL (catalog AK-205). Briefly, to 
determine the level of cAMP in the heart, LV tissue was homogenized in 10 
volumes of 0.1 M hydrochloric acid. For determination of cAMP content 
in isolated mouse LV myocytes and NRVMs, 106 cells were sonicated in 
300 μl of 0.1 M hydrochloric acid. Thereafter, the procedure followed the 
manufacturer’s instructions.
Echocardiographic and hemodynamic analysis of cardiac function. Transthorac-
ic 2-dimensional echocardiography (TTE) was performed in anesthetized 
(2% inhaled isoflurane) WT and Gsk3a–/– (KO) mice with a 12-MHz probe 
(39, 41). TTE in M-mode was carried out in the parasternal short-axis 
view to assess LV end-diastolic and end-systolic diameters and function 
(assessed as fractional shortening).
For in vivo hemodynamic measurements, a 1.4 French micromanom-
eter-tipped catheter (SPR-671; Millar Instruments Inc.) was inserted 
into the right carotid artery and advanced into the LV of mice that 
were lightly anesthetized (i.e., maintained spontaneous respirations) 
Figure 6
Contractile function of cardiomyocytes 
isolated from WT and KO mice. (A and 
B) Cardiomyocytes were isolated from 
4-month-old (A) and 2-month-old (B) WT 
and KO mice, as described in Methods. 
Basal and isoproterenol-stimulated frac-
tional shortening were determined at a 
5 × 10–7 M concentration of isoproterenol. 
Representative tracings from WT and KO 
cells and quantification are shown graphi-
cally. (A) Quantification is derived from 14 
WT and 14 KO cells derived from mice 
(n = 6). (B) Quantification is from 23 WT 
and 23 KO cells derived from mice (n = 6).
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with tribromoethanol/amylene hydrate (2.5% wt/vol, 8 μl/g injected 
intraperitoneal; Avertin). Hemodynamic parameters, including heart 
rate, LV end-diastolic pressure, and +dP/dt and –dP/dt, were recorded in 
closed-chest mode, both at baseline and in response to increasing doses 
of isoproterenol (0.1, 0.5, 1, 5, and 10 ng), administered via cannulation 
of the right internal jugular vein (42).
For the studies with NKH477 (catalog 1063; TOCRIS), mice were 
anesthetized and instrumented as above. NKH477 was dissolved in 
PBS and was administered in doses of 1, 10, 100, and 1,000 μg/kg in 
5-minute intervals, thereby allowing peak contractile function to be 
reached prior to dose escalation. Hemodynamic parameters were exact-
ly as described above.
TAC. TAC was performed as previously described (39). Briefly, mice 
were sedated with isoflurane (induction, 3%; maintenance, 1.5%) and 
anesthetized to a surgical plane with intraperitoneal ketamine (50 mg/kg) 
and xylazine (2.5 mg/kg). Anesthetized mice were intubated, and a 
midline cervical incision was made to expose the trachea and carotid 
arteries. A blunt 20-gauge needle was inserted into the trachea and con-
Figure 7
Normal contractile function in the KO mice following direct activation of adenylyl cyclase. (A) cAMP production in 4-month-old WT and KO hearts, 
following graded NKH477 infusion, as described in Methods. n = 5 WT and 5 KO control hearts; n = 7 WT and 6 KO hearts treated with NKH477. 
(B–E) Hemodynamic response to graded NKH477 infusion. LVSP (B), +dP/dt (C), -dP/dt (D), and heart rate (E). BL, baseline measurement prior 
to administration of NKH477 versus vehicle. n = 9 WT and 7 KO hearts.
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nected to a volume-cycled rodent ventilator on supplemental oxygen 
at a rate of 1 l/min, with a respiratory rate of 140 breaths/min. Aortic 
constriction was performed by tying a 7-0 nylon suture ligature against 
a 27-gauge needle. The needle was then promptly removed to yield a 
constriction of approximately 0.4 mm in diameter. LVSP was deter-
mined by in vivo hemodynamics, with a high fidelity pressure trans-
ducer advanced to the LV.
Transmission electron microscopy. Transmission electron microscopy was 
performed as previously described (41, 43).
Statistics. Comparisons between 2 groups were performed using 2-tailed 
Student’s t test. Comparisons between multiple groups were performed 
using 1-way ANOVA with Holm-Sidak post-test using SigmaStat software 
(Systat). All data are presented as mean ± SEM, except the tables, which are 
mean ± SD. A P value of less than 0.05 was considered significant.
Figure 8
GSK-3α regulates isoproterenol-induced cAMP production. (A–C) Studies were in 4-month-old mice. (A) cAMP production in the intact mouse 
heart. KO and WT mice were injected with isoproterenol (1 ng/g BW) versus vehicle. Fifteen minutes later, hearts were excised, and cAMP produc-
tion was determined. n = 4 mice per condition. (B) cAMP production in response to vehicle versus isoproterenol (5 μM, 15 minutes) in cardiomyo-
cytes isolated from KO and WT mice (n = 6), with 4 × 105 myocytes per assay. LVM, LV myocyte. (C) Inhibition of isoproterenol-induced contrac-
tile function by a GSK-3 inhibitor. Cardiomyocytes were isolated from WT and KO mice (n = 6). Fractional shortening was determined at baseline, 
after isoproterenol (5 μM, 10 minutes), and in WT cells pretreated with SB415286 (10 μM, 60 minutes). Contractile function increased with 
isoproterenol in WT cells but not in KO cells or SB415286-treated WT cells. n = 14 cells for WT and KO mice; n = 12 cells for WT plus SB415286 
mice. (D) SB415286 blocks cAMP production in NRVMs. NRVMs were pretreated with SB415286 or vehicle, followed by isoproterenol versus 
vehicle. SB415286 reduced isoproterenol-induced cAMP production but not forskolin-induced cAMP production. (E) Reduced isoproterenol-
induced phosphorylation of PLN in the KO mice. Two-month-old WT and KO mice underwent isoproterenol infusion (1 μg/kg BW) for 15 minutes. 
Lysates were immunoblotted for PLN phosphorylated at Ser16 (PKA site), Thr17 (CamKII site), total PLN, and GAPDH. (F) Increased iso-
proterenol-induced ERK1/2 activation in the KO mice. Mice were treated with isoproterenol versus vehicle as above, and cell lysates were 
immunoblotted for phospho-ERK1/2, total ERK1/2, phospho-p38, total p38, or GAPDH.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 120   Number 7   July 2010 2291
All procedures herein were approved by the Institutional Animal Care 
and Use Committee of Thomas Jefferson University.
Acknowledgments
This work was supported by NIH grants HL061688 and HL091799 
(to T. Force), by the Canadian Institutes of Health Research grants 
MOP 12858 and 74711 (to J. Woodgett), and by donations from 
The Kahn Foundation and the Scarperi family.
Received for publication October 12, 2009, and accepted in revised 
form April 7, 2010.
Address correspondence to: Thomas Force, Center for Translation-
al Medicine, Cardiology Division, Thomas Jefferson University, 
College Building, Rm. 316, 1025 Walnut St., Philadelphia, Penn-
sylvania 19107, USA. Phone: 215.503.9520; Fax: 215.503.5731; 
E-mail: thomas.force@jefferson.edu.
 1. Doble BW, Woodgett JR. GSK-3: tricks of the 
trade for a multi-tasking kinase. J Cell Sci. 2003; 
116(pt 7):1175–1186.
 2. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A. 
Glycogen synthase kinase 3: more than a namesake. 
Br J Pharmacol. 2009;156(6):885–898.
 3. Force T, Woodgett JR. Unique and overlapping 
functions of GSK-3 isoforms in cell differentiation 
and proliferation and cardiovascular development. 
J Biol Chem. 2009;284(15):9643–9647.
 4. Ruel L, Bourouis M, Heitzler P, Pantesco V, 
Simpson P. Drosophila shaggy kinase and rat 
glycogen synthase kinase-3 have conserved 
activities and act downstream of Notch. Nature. 
1993;362(6420):557–560.
 5. Siegel JN, Klausner RD, Rapp UR, Samelson LE. 
T cell antigen receptor engagement stimulates c-
raf phosphorylation and induces c-raf associated 
kinase activity via a protein kinase C-dependent 
pathway. J Biol Chem. 1990;265(30):18472–18480.
 6. Doble BW, Patel S, Wood GA, Kockeritz LK, Wood-
gett JR. Functional redundancy of GSK-3alpha and 
GSK-3beta in Wnt/beta-catenin signaling shown by 
using an allelic series of embryonic stem cell lines. 
Dev Cell. 2007;12(6):957–971.
 7. Kerkela R, et al. Deletion of GSK-3beta in mice 
leads to hypertrophic cardiomyopathy secondary 
to cardiomyoblast hyperproliferation. J Clin Invest. 
2008;118(11):3609–3618.
 8. Antos CL, et al. Activated glycogen synthase kinase-3β 
suppresses cardiac hypertrophy in vivo. Proc Natl 
Acad Sci U S A. 2002;99(2):907–912.
 9. Michael A, et al. Glycogen synthase kinase-3β 
regulates growth, calcium homeostasis, and 
diastolic function in the heart. J Biol Chem. 
2004;279(20):21383–21393.
 10. Sanbe A, Gulick J, Hanks MC, Liang Q, Osinska 
H, Robbins J. Reengineering inducible cardiac-spe-
cific transgenesis with an attenuated myosin heavy 
chain promoter. Circ Res. 2003;92(6):609–616.
 11. Trivedi CM, et al. Hdac2 regulates the cardiac 
hypertrophic response by modulating Gsk3beta 
activity. Nat Med. 2007;13(3):324–331.
 12. Hirotani S, et al. Inhibition of glycogen synthase 
kinase 3beta during heart failure is protective. Circ 
Res. 2007;101(11):1164–1174.
 13. Matsuda T, et al. Distinct roles of GSK-3alpha 
and GSK-3beta phosphorylation in the heart 
under pressure overload. Proc Natl Acad Sci U S A. 
2008;105(52):20900–20905.
 14. Zhai P, et al. Glycogen synthase kinase-3alpha 
reduces cardiac growth and pressure overload-
induced cardiac hypertrophy by inhibition of 
extracellular signal-regulated kinases. J Biol Chem. 
2007;282(45):33181–33191.
 15. Bikkavilli RK, Feigin ME, Malbon CC. p38 mitogen-
activated protein kinase regulates canonical Wnt-
beta-catenin signaling by inactivation of GSK3beta. 
J Cell Sci. 2008;121(pt 21):3598–3607.
 16. Thornton TM, et al. Phosphorylation by p38 MAPK 
as an alternative pathway for GSK3beta inactivation. 
Science. 2008;320(5876):667–670.
 17. McManus EJ, et al. Role that phosphorylation of 
GSK3 plays in insulin and Wnt signaling defined by 
knockin analysis. EMBO J. 2005;24(8):1571–1583.
 18. Patel S, Doble BW, MacAulay K, Sinclair EM, 
Drucker DJ, Woodgett JR. Tissue-specific role 
of glycogen synthase kinase 3beta in glucose 
homeostasis and insulin action. Mol Cell Biol. 
2008;28(20):6314–6328.
 19. Tanabe K, et al. Genetic deficiency of glycogen syn-
thase kinase-3beta corrects diabetes in mouse mod-
els of insulin resistance. PLoS Biol. 2008;6(2):e37.
 20. MacAulay K, et al. Glycogen synthase kinase 
3alpha-specific regulation of murine hepatic gly-
cogen metabolism. Cell Metab. 2007;6(4):329–337.
 21. Nagy A. Cre recombinase: the universal reagent for 
genome tailoring. Genesis. 2000;26(2):99–109.
 22. Arad M, et al. Glycogen storage diseases present-
ing as hypertrophic cardiomyopathy. N Engl J Med. 
2005;352(4):362–372.
 23. Sarbassov DD, Ali SM, Sabatini DM. Growing 
roles for the mTOR pathway. Curr Opin Cell Biol. 
2005;17(6):596–603.
 24. Sanbe A, Takeo S. Effects of NKH477, a water-soluble 
forskolin derivative, on cardiac function in rats with 
chronic heart failure after myocardial infarction.  
J Pharmacol Exp Ther. 1995;274(1):120–126.
 25. Das S, Wong R, Rajapakse N, Murphy E, Steenber-
gen C. Glycogen synthase kinase 3 inhibition slows 
mitochondrial adenine nucleotide transport and 
regulates voltage-dependent anion channel phos-
phorylation. Circ Res. 2008;103(9):983–991.
 26. Peineau S, et al. LTP inhibits LTD in the hip-
pocampus via regulation of GSK3beta. Neuron. 
2007;53(5):703–717.
 27. Patel PA, Tilley DG, Rockman HA. Physiologic and 
cardiac roles of beta-arrestins. J Mol Cell Cardiol. 
2009;46(3):300–308.
 28. Patel PA, Tilley DG, Rockman HA. Beta-arres-
tin-mediated signaling in the heart. Circ J. 
2008;72(11):1725–1729.
 29. Sugden PH, Fuller SJ, Weiss SC, Clerk A. Glycogen 
synthase kinase 3 (GSK3) in the heart: a point of 
integration in hypertrophic signalling and a thera-
peutic target? A critical analysis. Br J Pharmacol. 
2008;153 suppl 1:S137–S153.
 30. Huang J, Manning BD. The TSC1-TSC2 complex: 
a molecular switchboard controlling cell growth. 
Biochem J. 2008;412(2):179–190.
 31. Inoki K, et al. TSC2 integrates Wnt and energy 
signals via a coordinated phosphorylation by 
AMPK and GSK3 to regulate cell growth. Cell. 
2006;126(5):955–968.
 32. Li M, Wang X, Meintzer MK, Laessig T, Birn-
baum MJ, Heidenreich KA. Cyclic AMP pro-
motes neuronal survival by phosphorylation 
of glycogen synthase kinase 3beta. Mol Cell Biol. 
2000;20(24):9356–9363.
 33. Taurin S, Hogarth K, Sandbo N, Yau DM, Dulin 
NO. Gbetagamma-mediated prostacyclin pro-
duction and cAMP-dependent protein kinase 
activation by endothelin-1 promotes vascular 
smooth muscle cell hypertrophy through inhibi-
tion of glycogen synthase kinase-3. J Biol Chem. 
2007;282(27):19518–19525.
 34. Rowe MK, Wiest C, Chuang DM. GSK-3 is a 
viable potential target for therapeutic interven-
tion in bipolar disorder. Neurosci Biobehav Rev. 
2007;31(6):920–931.
 35. Murphy E, Steenbergen C. Does inhibition of gly-
cogen synthase kinase protect in mice? Circ Res. 
2008;103(3):226–228.
 36. Klapholz M. Beta-blocker use for the stages of heart 
failure. Mayo Clin Proc. 2009;84(8):718–729.
 37. Chen X, et al. Ca2+ influx-induced sarcoplasmic 
reticulum Ca2+ overload causes mitochondrial-
dependent apoptosis in ventricular myocytes. Circ 
Res. 2005;97(10):1009–1017.
 38. Chen X, et al. Reduced effects of BAY K 8644 on L-type 
Ca2+ current in failing human cardiac myocytes are 
related to abnormal adrenergic regulation. Am J Physiol 
Heart Circ Physiol. 2008;294(5):H2257–H2267.
 39. Chen X, et al. The β-catenin/T-cell factor/Lympho-
cyte enhancer factor signaling pathway is required 
for normal and stress-induced cardiac hypertrophy. 
Mol Cell Biol. 2006;26(12):4462–4473.
 40. Jaleel N, et al. Ca2+ influx through T- and L-type 
Ca2+ channels have different effects on myocyte 
contractility and induce unique cardiac phenotypes. 
Circ Res. 2008;103(10):1109–1119.
 41. Kerkela R, et al. Cardiotoxicity of the cancer 
therapeutic agent imatinib mesylate. Nat Med. 
2006;12(8):908–916.
 42. Gao E, Boucher M, Chuprun JK, Zhou RH, Eck-
hart AD, Koch WJ. Darbepoetin alfa, a long-acting 
erythropoietin analog, offers novel and delayed car-
dioprotection for the ischemic heart. Am J Physiol 
Heart Circ Physiol. 2007;293(1):H60–H68.
 43. Chu T, et al. Cardiotoxicity associated with 
the tyrosine kinase inhibitor sunitinib. Lancet. 
2007;370(9604):2011–2019.
